The stock is currently trading below that of its peers, despite the robust 3Q15 guidance of about 55 percent year on year growth, increase in margins, as well as future catalysts, such as the GoPro drone, which isexpected to be launched in 1Q16, virtual reality apps being launched and increasing contribution of the company’s media initiatives.
The Fly On The Wall
Valeant analyst commentary
Valeant weakness an opportunity , says BofA/Merrill. BofA/Merrill analyst Sumant S. Kulkarni believes Valeant's diverse business mix and asset base, with low relative product-concentration risk, will drive robustcash flow and help deleverage to less than 4x adjusted EBITDA by the end of 2016.
Kulkarni price target on Valeant shares $173 and maintains his Buy rating
Buprenorphine -This drug is intended for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term treatment
check out one month chart- im a buyer
Good Link. Only 6 Trade Days Until Earnings- All In
Sentiment: Strong Buy
think Im kidding.
we will see